TY - JOUR
T1 - The Use of Extracorporeal Life Support in Children With Immune-Mediated Diseases
AU - Barreto, Jessica A.
AU - Mehta, Amit
AU - Thiagarajan, Ravi R.
AU - Hayward, Kristen N.
AU - Brogan, Adrian
AU - Brogan, Thomas V.
N1 - Funding Information:
Dr. Thiagarajan’s institution received funding from Bristol Myers Squibb; he received funding from Pfizer, Advocate Children’s Hospital, and Society of Critical Care Medicine Pediatric Board Review Course. Dr. Hayward disclosed that she is a stockholder in Abbie, Merk and Co, and Teva Pharmaceuticals; she disclosed the off-label product uses of drugs in pediatric rheumatology. The remaining authors disclosed that they do not have any potential conflicts of interest.
Publisher Copyright:
© 2021 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
PY - 2022/1/1
Y1 - 2022/1/1
N2 - OBJECTIVES: To describe the use and outcomes of extracorporeal membrane oxygenation support among children with immune-mediated conditions. DESIGN: Retrospective cohort study. SETTING: The Extracorporeal Life Support Organization registry. PATIENTS: Patients 1 month to 18 years old with International Classification of Diseases, 9th Edition and International Classification of Diseases, 10th Edition codes for immune-mediated conditions from 1989 to 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: During the study period, 207 patients with an immune-mediated condition received extracorporeal membrane oxygenation, and 50% survived to discharge. Most patients (63%) received extracorporeal membrane oxygenation for respiratory support with 53% survival, 21% received cardiac support (55% survival), and 15% received extracorporeal cardiopulmonary resuscitation (34% survival). The most common diagnosis among nonsurvivors was hemophagocytic lymphohistiocytosis/macrophage activation syndrome with 37% survival. Patients with juvenile idiopathic arthritis (23%) and dermatomyositis (25%) had the lowest survival. Nonsurvivors had a higher frequency of infections, neurologic complications, and renal replacement therapy use. Use of preextracorporeal membrane oxygenation corticosteroids was associated with mortality. CONCLUSIONS: Children with immune-mediated conditions can be successfully supported with extracorporeal membrane oxygenation. Extracorporeal membrane oxygenation use has increased over time, and survival varies considerably by diagnosis.
AB - OBJECTIVES: To describe the use and outcomes of extracorporeal membrane oxygenation support among children with immune-mediated conditions. DESIGN: Retrospective cohort study. SETTING: The Extracorporeal Life Support Organization registry. PATIENTS: Patients 1 month to 18 years old with International Classification of Diseases, 9th Edition and International Classification of Diseases, 10th Edition codes for immune-mediated conditions from 1989 to 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: During the study period, 207 patients with an immune-mediated condition received extracorporeal membrane oxygenation, and 50% survived to discharge. Most patients (63%) received extracorporeal membrane oxygenation for respiratory support with 53% survival, 21% received cardiac support (55% survival), and 15% received extracorporeal cardiopulmonary resuscitation (34% survival). The most common diagnosis among nonsurvivors was hemophagocytic lymphohistiocytosis/macrophage activation syndrome with 37% survival. Patients with juvenile idiopathic arthritis (23%) and dermatomyositis (25%) had the lowest survival. Nonsurvivors had a higher frequency of infections, neurologic complications, and renal replacement therapy use. Use of preextracorporeal membrane oxygenation corticosteroids was associated with mortality. CONCLUSIONS: Children with immune-mediated conditions can be successfully supported with extracorporeal membrane oxygenation. Extracorporeal membrane oxygenation use has increased over time, and survival varies considerably by diagnosis.
KW - Adolescent
KW - Child
KW - Complex chronic conditions
KW - Extracorporeal life support organization
KW - Extracorporeal membrane oxygenation
KW - Immune system diseases
UR - http://www.scopus.com/inward/record.url?scp=85123316686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123316686&partnerID=8YFLogxK
U2 - 10.1097/PCC.0000000000002801
DO - 10.1097/PCC.0000000000002801
M3 - Article
C2 - 34261943
AN - SCOPUS:85123316686
SN - 1529-7535
VL - 23
SP - E60-E65
JO - Pediatric Critical Care Medicine
JF - Pediatric Critical Care Medicine
IS - 1
ER -